Skip to main content
SpringerLink
Log in

Alternative Splicing in Breast Cancer

  • Chapter
  • First Online:
Molecular Pathology of Breast Cancer

  • 1378 Accesses

Abstract

Alternative splicing of pre-mRNA is an essential event that leads to protein diversity and regulation of the cellular processes in mammals. With the advent of the next generation sequencing technologies, the role of alternative splicing is gaining a momentum. Regulation of alternative splicing is a complex process involving the core spliceosome machinery and multiple regulatory factors that enable the tightly controlled splicing of introns/exons. Any aberrant alteration in this process can result in diseases such as cancer. Indeed, accumulating evidence suggests that alternative splicing plays an important role in all hallmarks of cancer including proliferative signaling, resisting cell death, inducing angiogenesis, and activating invasion and metastasis. These changes may occur due to mutations or altered expression levels of key regulatory genes of spliceosome machinery or splicing factors. In this review, we summarize recent findings that have implicated the critical role of alternative splicing in breast cancer and discuss current understandings and its potential utility in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26(9):1324–1337. doi:10.1038/sj.onc.1210220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ahlborn LB, Dandanell M, Steffensen AY, Jonson L, Nielsen FC, Hansen TV (2015) Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic. Breast Cancer Res Treat 150(2):289–298. doi:10.1007/s10549-015-3313-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F (2001) Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 20(17):2101–2111. doi:10.1038/sj.onc.1204305

    Article  CAS  PubMed  Google Scholar 

  • Akgul C, Moulding DA, Edwards SW (2004) Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 61(17):2189–2199. doi:10.1007/s00018-004-4001-7

    Article  CAS  PubMed  Google Scholar 

  • Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7):3983–3988. doi:10.1073/pnas.0530291100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anczukow O, Akerman M, Clery A, Wu J, Shen C, Shirole NH, Raimer A, Sun S, Jensen MA, Hua Y, Allain FH, Krainer AR (2015) SRSF1-regulated alternative splicing in breast cancer. Mol Cell 60(1):105–117. doi:10.1016/j.molcel.2015.09.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anczukow O, Buisson M, Salles MJ, Triboulet S, Longy M, Lidereau R, Sinilnikova OM, Mazoyer S (2008) Unclassified variants identified in BRCA1 exon 11: consequences on splicing. Genes Chromosomes Cancer 47(5):418–426. doi:10.1002/gcc.20546

    Article  CAS  PubMed  Google Scholar 

  • Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Australian Pancreatic Cancer Genome I, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491(7424):399–405. doi:10.1038/nature11547

    Google Scholar 

  • Biselli-Chicote PM, Oliveira AR, Pavarino EC, Goloni-Bertollo EM (2012) VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. J Cancer Res Clin Oncol 138(3):363–370. doi:10.1007/s00432-011-1073-2

    Article  CAS  PubMed  Google Scholar 

  • Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291–336. doi:10.1146/annurev.biochem.72.121801.161720

    Article  CAS  PubMed  Google Scholar 

  • Blencowe BJ (2006) Alternative splicing: new insights from global analyses. Cell 126(1):37–47. doi:10.1016/j.cell.2006.06.023

    Article  CAS  PubMed  Google Scholar 

  • Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74(4):597–608

    Article  CAS  PubMed  Google Scholar 

  • Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, Berthet P, Chevrier A, Dugast C, Layet V, Rossi A, Lidereau R, Frebourg T, Hardouin A, Tosi M (2008) Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45(7):438–446. doi:10.1136/jmg.2007.056895

    Article  CAS  PubMed  Google Scholar 

  • Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C (2011) CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121(3):1064–1074. doi:10.1172/JCI44540

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412

    Article  Google Scholar 

  • Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI (2006) The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 1765(2):85–100. doi:10.1016/j.bbcan.2005.10.002

    CAS  PubMed  Google Scholar 

  • Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4):285–298. doi:10.1038/nrg775

    Article  CAS  PubMed  Google Scholar 

  • Caux-Moncoutier V, Pages-Berhouet S, Michaux D, Asselain B, Castera L, De Pauw A, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Houdayer C (2009) Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 17(11):1471–1480. doi:10.1038/ejhg.2009.89

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cha JY, Lambert QT, Reuther GW, Der CJ (2008) Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 6(3):435–445. doi:10.1158/1541-7786.MCR-07-0187

    Article  CAS  PubMed  Google Scholar 

  • Chen J, Weiss WA (2015) Alternative splicing in cancer: implications for biology and therapy. Oncogene 34(1):1–14. doi:10.1038/onc.2013.570

    Article  PubMed  Google Scholar 

  • Cho H, Davis J, Li X, Smith KS, Battle A, Montgomery SB (2014) High-resolution transcriptome analysis with long-read RNA sequencing. PLoS ONE 9(9):e108095. doi:10.1371/journal.pone.0108095

    Article  PubMed  PubMed Central  Google Scholar 

  • Cloutier P, Toutant J, Shkreta L, Goekjian S, Revil T, Chabot B (2008) Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. J Biol Chem 283(31):21315–21324. doi:10.1074/jbc.M800353200

    Article  CAS  PubMed  Google Scholar 

  • David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24(21):2343–2364. doi:10.1101/gad.1973010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM (1999) The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A 96(19):10869–10874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dutertre M, Vagner S, Auboeuf D (2010) Alternative splicing and breast cancer. RNA Biol 7(4):403–411

    Article  CAS  PubMed  Google Scholar 

  • Dvinge H, Bradley RK (2015) Widespread intron retention diversifies most cancer transcriptomes. Genome Med 7(1):45. doi:10.1186/s13073-015-0168-9

    Article  PubMed  PubMed Central  Google Scholar 

  • Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE (2007) A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81(5):873–883. doi:10.1086/521032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353–360. doi:10.1038/nature11143

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fletcher MN, Castro MA, Wang X, de Santiago I, O’Reilly M, Chin SF, Rueda OM, Caldas C, Ponder BA, Markowetz F, Meyer KB (2013) Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun 4:2464. doi:10.1038/ncomms3464

    PubMed  PubMed Central  Google Scholar 

  • Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R (2013) SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 3(10):1122–1129. doi:10.1158/2159-8290.CD-13-0330

    Article  CAS  PubMed  Google Scholar 

  • Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2):139–147

    Article  CAS  PubMed  Google Scholar 

  • Germann S, Gratadou L, Dutertre M, Auboeuf D (2012) Splicing programs and cancer. J Nucleic Acids 2012:269570. doi:10.1155/2012/269570

    Article  PubMed  Google Scholar 

  • Gokmen-Polar Y, Neelamraju Y, Goswami CP, Gu X, Nallamothu G, Janga SC, Badve S (2015) Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Mod Pathol 28(5):677–685. doi:10.1038/modpathol.2014.146

    Article  CAS  PubMed  Google Scholar 

  • Grosso AR, Martins S, Carmo-Fonseca M (2008) The emerging role of splicing factors in cancer. EMBO Rep 9(11):1087–1093. doi:10.1038/embor.2008.189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, Brown LF (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80(10):1945–1953

    Article  CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Article  CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013

    Article  CAS  PubMed  Google Scholar 

  • Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM (2013) Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45(2):133–135. doi:10.1038/ng.2523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Harper SJ, Bates DO (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8(11):880–887. doi:10.1038/nrc2505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS (2008) The role of metastasis suppressor genes in metastatic dormancy. APMIS 116(7–8):586–601. doi:10.1111/j.1600-0463.2008.01213.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5(12):1806–1814. doi:10.1210/mend-5-12-1806

    Article  CAS  PubMed  Google Scholar 

  • Inoue K (2015) Fry EA (2015) Aberrant splicing of estrogen receptor, HER2, and CD44 genes in breast cancer. Genet Epigenet. 2(7):19–32. doi:10.4137/GEG.S35500

    Article  Google Scholar 

  • Irimia M, Blencowe BJ (2012) Alternative splicing: decoding an expansive regulatory layer. Curr Opin Cell Biol 24(3):323–332. doi:10.1016/j.ceb.2012.03.005

    Article  CAS  PubMed  Google Scholar 

  • Jackson C, Browell D, Gautrey H, Tyson-Capper A (2013) Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int J Cell Biol 2013:973584. doi:10.1155/2013/973584

    Article  PubMed  PubMed Central  Google Scholar 

  • Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14(3):185–193. doi:10.1038/nsmb1209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Koletsa T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, Kotoula V (2008) A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia 10(7):687–696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD (2004) Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10(5):1706–1716

    Article  CAS  PubMed  Google Scholar 

  • Liu HX, Cartegni L, Zhang MQ, Krainer AR (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27(1):55–58. doi:10.1038/83762

    Article  CAS  PubMed  Google Scholar 

  • Liu S, Cheng C (2013) Alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA 4(5):547–566. doi:10.1002/wrna.1178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Loh TJ, Moon H, Cho S, Jang H, Liu YC, Tai H, Jung DW, Williams DR, Kim HR, Shin MG, Liao DJ, Zhou J, Shi W, Zheng X, Shen H (2015) CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer. Oncol Rep 34(3):1231–1238. doi:10.3892/or.2015.4110

    PubMed  Google Scholar 

  • Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E, Jenkins M, Renard H, Hopper J, Waring P, Tavtigian SV, Goldgar D, Lindeman GJ, Visvader JE, Couch FJ, Henderson BR, Southey M, Chenevix-Trench G, Spurdle AB, Brown MA, kConFab I (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43(1):74–83. doi:10.1136/jmg.2005.033258

    Google Scholar 

  • Ma X, Zhao Y, Li Y, Lu H, He Y (2010) Relevance of Bcl-x expression in different types of endometrial tissues. J Exp Clin Cancer Res 29:14. doi:10.1186/1756-9966-29-14

    Article  PubMed  PubMed Central  Google Scholar 

  • Maguire SL, Leonidou A, Wai P, Marchio C, Ng CK, Sapino A, Salomon AV, Reis-Filho JS, Weigelt B, Natrajan RC (2015) SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol 235(4):571–580. doi:10.1002/path.4483

    Article  CAS  PubMed  Google Scholar 

  • Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, Galli A, Da Via MC, Conte S, Tauro S, Keenan N, Hyslop A, Hinton J, Mudie LJ, Wainscoat JS, Futreal PA, Stratton MR, Campbell PJ, Hellstrom-Lindberg E, Cazzola M, Chronic Myeloid Disorders Working Group of the International Cancer Genome C, of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie M (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 118(24):6239–6246. doi:10.1182/blood-2011-09-377275

    Google Scholar 

  • McManus CJ, Graveley BR (2011) RNA structure and the mechanisms of alternative splicing. Curr Opin Genet Dev 21(4):373–379. doi:10.1016/j.gde.2011.04.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C (2010) The c.5242C> A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 120(2):391–399. doi:10.1007/s10549-009-0392-3

    Article  CAS  PubMed  Google Scholar 

  • Moffa AB, Tannheimer SL, Ethier SP (2004) Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2(11):643–652

    CAS  PubMed  Google Scholar 

  • Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO (2008) Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121(Pt 20):3487–3495. doi:10.1242/jcs.016410

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringner M, Vallon-Christersson J, Jonsson G, Holm K, Lovgren K, Ferno M, Grabau D, Borg A, Hegardt C (2011) CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11:418. doi:10.1186/1471-2407-11-418

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Oltean S, Bates DO (2014) Hallmarks of alternative splicing in cancer. Oncogene 33(46):5311–5318. doi:10.1038/onc.2013.533

    Article  CAS  PubMed  Google Scholar 

  • Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40(12):1413–1415. doi:10.1038/ng.259

    Article  CAS  PubMed  Google Scholar 

  • Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ, Chronic Myeloid Disorders Working Group of the International Cancer Genome C (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365(15):1384–1395. doi:10.1056/NEJMoa1103283

    Google Scholar 

  • Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Gine E, Hernandez JM, Gonzalez-Diaz M, Puente DA, Velasco G, Freije JM, Tubio JM, Royo R, Gelpi JL, Orozco M, Pisano DG, Zamora J, Vazquez M, Valencia A, Himmelbauer H, Bayes M, Heath S, Gut M, Gut I, Estivill X, Lopez-Guillermo A, Puente XS, Campo E, Lopez-Otin C (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44(1):47–52. doi:10.1038/ng.1032

    Article  CAS  Google Scholar 

  • Ramsay AJ, Rodriguez D, Villamor N, Kwarciak A, Tejedor JR, Valcarcel J, Lopez-Guillermo A, Martinez-Trillos A, Puente XS, Campo E, Lopez-Otin C, Quesada V (2013) Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia. Leukemia 27(7):1600–1603. doi:10.1038/leu.2012.344

    Article  CAS  PubMed  Google Scholar 

  • Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969

    CAS  PubMed  Google Scholar 

  • Romero A, Garcia-Garcia F, Lopez-Perolio I, Ruiz de Garibay G, Garcia-Saenz JA, Garre P, Ayllon P, Benito E, Dopazo J, Diaz-Rubio E, Caldes T, de la Hoya M (2015) BRCA1 Alternative splicing landscape in breast tissue samples. BMC Cancer 15:219. doi:10.1186/s12885-015-1145-9

    Article  PubMed  PubMed Central  Google Scholar 

  • Scott LM, Rebel VI (2013) Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. J Natl Cancer Inst 105(20):1540–1549. doi:10.1093/jnci/djt257

    Article  CAS  PubMed  Google Scholar 

  • Screaton GR, Bell MV, Bell JI, Jackson DG (1993) The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 268(17):12235–12238

    CAS  PubMed  Google Scholar 

  • Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59. doi:10.1186/bcr1610

    Article  PubMed  PubMed Central  Google Scholar 

  • Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3):259–273. doi:10.1016/j.ccr.2007.01.013

    Article  CAS  PubMed  Google Scholar 

  • Silipo M, Gautrey H, Tyson-Capper A (2015) Deregulation of splicing factors and breast cancer development. J Mol Cell Biol 7(5): 388–401

    Google Scholar 

  • Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerod A, Oslo Breast Cancer C, Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van ‘t Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Borresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400–404. doi:10.1038/nature11017

    Google Scholar 

  • Swami V, Arteche A, Chamorro-Premuzic T, Maakip I, Stanistreet D, Furnham A (2009) Lay perceptions of current and future health, the causes of illness, and the nature of recovery: explaining health and illness in Malaysia. Br J Health Psychol 14(Pt 3):519–540. doi:10.1348/135910708X370781 308587 [pii]

    Article  PubMed  Google Scholar 

  • Tammaro C, Raponi M, Wilson DI, Baralle D (2012) BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer. Biochem Soc Trans 40(4):768–772. doi:10.1042/BST20120140

    Article  CAS  PubMed  Google Scholar 

  • Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J, Sakaguchi I, Honda R, Tashiro H, Katabuchi H (2015) CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. Cancer Sci 106(10):1421–1428. doi:10.1111/cas.12765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A (2008) Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 644(1–2):64–70. doi:10.1016/j.mrfmmm.2008.07.005

    Article  CAS  PubMed  Google Scholar 

  • Twyffels L, Gueydan C, Kruys V (2011) Shuttling SR proteins: more than splicing factors. FEBS J 278(18):3246–3255. doi:10.1111/j.1742-4658.2011.08274.x

    Article  CAS  PubMed  Google Scholar 

  • Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, Gervais-Bird J, Lapointe E, Froehlich U, Durand M, Gendron D, Brosseau JP, Thibault P, Lucier JF, Tremblay K, Prinos P, Wellinger RJ, Chabot B, Rancourt C, Elela SA (2008) Identification of alternative splicing markers for breast cancer. Cancer Res 68(22):9525–9531. doi:10.1158/0008-5472.CAN-08-1769

    Article  CAS  PubMed  Google Scholar 

  • Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365(26):2497–2506. doi:10.1056/NEJMoa1109016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP (2009) ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33(5):591–601. doi:10.1016/j.molcel.2009.01.025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wei W, Liu W, Cassol CA, Zheng W, Asa SL, Ezzat S (2012) The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-kappaB signaling. Mol Cell Biol 32(22):4662–4673. doi:10.1128/MCB.00935-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, Osawa T, Kanki Y, Minami T, Aburatani H, Ohmura M, Kubo A, Suematsu M, Takahashi K, Saya H, Nagano O (2012) Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 3:883. doi:10.1038/ncomms1892

    Article  PubMed  Google Scholar 

  • Yoshida K, Ogawa S (2014) Splicing factor mutations and cancer. Wiley Interdiscip Rev RNA 5(4):445–459. doi:10.1002/wrna.1222

    Article  CAS  PubMed  Google Scholar 

  • Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367):64–69. doi:10.1038/nature10496

    Article  CAS  PubMed  Google Scholar 

  • Zhang J, Manley JL (2013) Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov 3(11):1228–1237. doi:10.1158/2159-8290.CD-13-0253

    Article  CAS  PubMed  Google Scholar 

  • Zhang P, Fu C, Bai H, Song E, Dong C, Song Y (2014) CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells. FEBS Lett 588(24):4573–4582. doi:10.1016/j.febslet.2014.10.027

    Article  CAS  PubMed  Google Scholar 

  • Zhang P, Fu C, Bai H, Song E, Dong C, Song Y (2015) Corrigendum to “CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells” [FEBS Lett 588(24) (2014) 4573–4582]. FEBS Lett 589(4):553. doi:10.1016/j.febslet.2015.01.016

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 635 Barnhill Drive, MS 0038, Indianapolis, IN, 46202, USA

    Yesim Gökmen-Polar

Authors
  1. Yesim Gökmen-Polar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yesim Gökmen-Polar .

Editor information

Editors and Affiliations

  1. Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

    Sunil Badve

  2. Indiana University School of Medicine, Dept of Pathology & Laboratory Medicine Indiana University School of Medicine, Indianapolis, Indiana, USA

    Yesim Gökmen-Polar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gökmen-Polar, Y. (2016). Alternative Splicing in Breast Cancer. In: Badve, S., Gökmen-Polar, Y. (eds) Molecular Pathology of Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-41761-5_23

Download citation

Publish with us

Policies and ethics

Search

Navigation